In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ProQinase GMBH

Executive Summary

ProQinase GMBH was established as a wholly owned subsidiary of the Tumor Biology Centre (TBC), Freiburg, in April 2001 to commercialize the centre's research on protein kinases. During their years of basic research at TBC, ProQinase's scientists have developed extensive know-how in the protein kinase arena and have established a range of tools and assays to identify, produce, manipulate and screen protein kinases' activities. These tools and assays now constitute the Integrated Technology Platform Protein Kinases that ProQinase is commercializing through a hybrid business model. The company will apply the platform technology to its own in-house drug discovery and development activities and also make it available to external clients on a fee-for-service basis.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel